Disparities in Surgical Resection for Early Stage Pancreas Cancer in the Texas-Mexico Border Population

Metabolic alterations in malignant cells play a vital role in tumor initiation, proliferation, and metastasis. Biofluids from patients with non–small cell lung cancer (NSCLC) harbor metabolic biomarkers with potential clinical applications. In this study, we assessed the changes in the metabolic profile of patients with early-stage NSCLC using mass spectrometry and nuclear magnetic resonance spectroscopy before and after surgical resection. A single cohort of 35 patients provided a total of 29 and 32 pairs of urine and serum samples, respectively, pre-and post-surgery. We identified a profile of 48 metabolites that were significantly different pre- and post-surgery: 17 in urine and 31 in serum. A higher proportion of metabolites were upregulated than downregulated post-surgery (p < 0.01); however, the median fold change (FC) was higher for downregulated than upregulated metabolites (p < 0.05). Purines/pyrimidines and proteins had a larger dysregulation than other classes of metabolites (p < 0.05 for each class). Several of the dysregulated metabolites have been previously associated with cancer, including leucyl proline, asymmetric dimethylarginine, isopentenyladenine, fumaric acid (all downregulated post-surgery), as well as N6-methyladenosine and several deoxycholic acid moieties, which were upregulated post-surgery. This study establishes metabolomic analysis of biofluids as a path to non-invasive diagnostics, screening, and monitoring in NSCLC.

Download Full-text

Type 2 diabetes and tuberculosis in a dynamic bi-national border population

Epidemiology and Infection ◽

10.1017/s0950268806006935 ◽

2006 ◽

Vol 135 (3) ◽

pp. 483-491 ◽

Cited By ~ 89

Author(s):

B. I. RESTREPO ◽

S. P. FISHER-HOCH ◽

J. G. CRESPO ◽

E. WHITNEY ◽

A. PEREZ ◽

...

Keyword(s):

Type 2 Diabetes ◽

Large Population ◽

The United States ◽

South Texas ◽

Control Programmes ◽

Mexico Border ◽

Northeastern Mexico ◽

The Impact ◽

Border Population

The epidemic of type 2 diabetes in the United States prompted us to explore the association between diabetes and tuberculosis (TB) on the South Texas–Mexico border, in a large population of mostly non-hospitalized TB patients. We examined 6 years of retrospective data from all TB patients (n=5049) in South Texas and northeastern Mexico and found diabetes self-reported by 27·8% of Texan and 17·8% of Mexican TB patients, significantly exceeding national self-reported diabetes rates for both countries. Diabetes comorbidity substantially exceeded that of HIV/AIDS. Patients with TB and diabetes were older, more likely to have haemoptysis, pulmonary cavitations, be smear positive at diagnosis, and remain positive at the end of the first (Texas) or second (Mexico) month of treatment. The impact of type 2 diabetes on TB is underappreciated, and in the light of its epidemic status in many countries, it should be actively considered by TB control programmes, particularly in older patients.

Download Full-text

Osimertinib as neoadjuvant treatment for resectable stage II-IIIB EGFR mutant lung adenocarcinoma (NEOS).

Journal of Clinical Oncology ◽

10.1200/jco.2021.39.15_suppl.8524 ◽

2021 ◽

Vol 39 (15_suppl) ◽

pp. 8524-8524

Author(s):

Chao Lyu ◽

Wentao Fang ◽

Haitao Ma ◽

Jia Wang ◽

Wenjie Jiao ◽

...

Keyword(s):

Lung Adenocarcinoma ◽

Surgical Resection ◽

Interim Analysis ◽

Kinase Inhibitors ◽

Response Rate ◽

Early Stage ◽

Neoadjuvant Treatment ◽

Complete Response ◽

Stage Ii ◽

Meaningful Improvement

8524 Background: Neoadjuvant treatment has demonstrated efficacy in several types of cancer and is increasingly used for the treatment of early-stage cancers with the potential of cancer downstaging to enhance complete surgical resection and to improve clinical outcomes. Recent evidences have demonstrated that the neoadjuvant use of first/second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) may provide clinically meaningful improvement in EGFRm non-small cell lung cancer (NSCLC) patients, however, limited data were reported on osimertinib, the third-generation EGFR-TKI, in the neoadjuvant setting. Here we present an interim analysis of osimertinib as neoadjuvant treatment for resectable EGFRm NSCLC. Methods: NEOS is a prospective, multi-center, single-arm study to evaluate the efficacy and safety of osimertinib as neoadjuvant treatment in resectable EGFRm (19del/L858R) lung adenocarcinoma. Eligible patients were treated with osimertinib 80 mg orally per day for six weeks followed by surgery. Assessment of response to neoadjuvant therapy was performed according to RECIST 1.1. The primary endpoint was response rate. Secondary endpoints included safety, R0 surgical resection rate, quality of life, major pathologic response (MPR) rate, pathological complete response (pCR) rate, and N2 downstaging rate. Results: As of Dec. 17, 2020, 18 eligible patients (median age 61 [range 46-73], 27.8% male, 22.2% ECOG PS 1) have been enrolled. Patients with clinical stages IIa, IIb, and IIIa (8th AJCC) accounted for 16.7%, 22.2% and 61.1%, respectively. Half (9/18) of the patients had EGFR exon 21 L858R mutations and the other half (9/18) had EGFR exon 19del mutations. Amongst all 15 patients who completed efficacy assessment after neoadjuvant osimertinib, the response rate (RR) was 73.3% (11/15) and the disease control rate (DCR) was 100% (15/15). R0 surgical resection was performed in 93.3% (14/15) patients. Pathological downstaging occurred in 53.3% (8/15) patients. 42.9% (3/7) of the patients with confirmed N2 lymph nodes experienced downstaging to N0 disease after receiving neoadjuvant osimertinib. One patient was identified with a pCR. Adverse events (AEs) were reported in 66.7% (12/18) of patients, with the most common AE being rash (8/18, 44.4%), oral ulceration (8/18, 44.4%), and diarrhea (5/18, 27.8%). No grade 3-5 AEs or serious AEs were reported. Conclusions: Interim analysis from this study indicated neoadjuvant osimertinib as an effective and feasible treatment in patients with resectable stage II-IIIB EGFRm NSCLC. The trial is ongoing and the final results will be provided in the future. Clinical trial information: ChiCTR1800016948.

Download Full-text

Percutaneous ablation therapy versus surgical resection in the treatment for early-stage hepatocellular carcinoma: a meta-analysis of 21,494 patients

Journal of Cancer Research and Clinical Oncology ◽

10.1007/s00432-013-1530-1 ◽

2013 ◽

Vol 139 (12) ◽

pp. 2021-2033 ◽

Cited By ~ 25

Author(s):

Jia-yan Ni ◽

Lin-feng Xu ◽

Hong-liang Sun ◽

Jing-xing Zhou ◽

Yao-ting Chen ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Surgical Resection ◽

Early Stage ◽

Meta Analysis ◽

Percutaneous Ablation ◽

Ablation Therapy

Download Full-text

Age, tumor size, type of surgery, and gender predict survival in early stage (stage I and II) non-small cell lung cancer after surgical resection

Lung Cancer ◽

10.1016/j.lungcan.2009.08.008 ◽

2010 ◽

Vol 68 (3) ◽

pp. 398-402 ◽

Cited By ~ 32

Author(s):

Mohit Agarwal ◽

Govinda Brahmanday ◽

Gary W. Chmielewski ◽

Robert J. Welsh ◽

K.P. Ravikrishnan

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Surgical Resection ◽

Tumor Size ◽

Early Stage ◽

Small Cell ◽

Small Cell Lung ◽

Size Type ◽

And Gender ◽

Type Of Surgery

Download Full-text

Case Report: Carcinoma of Colon

Journal of Gastrointestinal Disorders and Liver Functions ◽

10.15436/2471-0601.18.1837 ◽

2018 ◽

Vol 4 (1) ◽

pp. 1-3

Author(s):

sushila ladumor ◽

Adham Darweesh

Keyword(s):

Colorectal Cancer ◽

Case Report ◽

Survival Rate ◽

Gastrointestinal Tract ◽

Colorectal Carcinoma ◽

Surgical Resection ◽

Early Stage ◽

Occult Lesion ◽

Carcinoma Of Colon ◽

Ct And Mri

Colorectal cancer is a disease that is curable if diagnosed at early stage and also it is preventable if predisposing adenomas are detected and removed. Colorectal Carcinoma (CRC) is commonest malignancy of the gastrointestinal tract and is the second most usually diagnosed cancer in adults, mainly at 6th to 7th decades of life[2]. CT and MRI are the modalities of choice used for staging. Colonoscopy for better evaluation and tissue diagnosis as well as to see other occult lesion. Surgical resection may be curative although five-year survival rate is 40 - 50 %.

Download Full-text

Clinical study of mucosa-associated lymphoid tissue lymphomas of the head and neck

The Journal of Laryngology & Otology ◽

10.1017/s0022215111002192 ◽

2011 ◽

Vol 126 (3) ◽

pp. 271-275

Author(s):

S Hosokawa ◽

J Okamura ◽

Y Takizawa ◽

G Takahashi ◽

K Hosokawa ◽

...

Keyword(s):

Head And Neck ◽

Surgical Resection ◽

Lymphoid Tissue ◽

Early Stage ◽

Local Treatment ◽

Response To Treatment ◽

Limited Information ◽

Early Stage Disease ◽

First Choice

AbstractBackground:Limited information is available on mucosa-associated lymphoid tissue lymphomas arising in the head and neck.Method:A retrospective analysis was conducted of 20 patients who were histologically diagnosed with mucosa-associated lymphoid tissue lymphoma and treated at our institution between January 1990 and December 2009.Results:Treatment consisted of surgical resection alone in two patients (10 per cent), surgical resection with consecutive radiotherapy in one (5 per cent), and radiotherapy alone in eight (40 per cent). Three patients (15 per cent) were treated with systemic chemotherapy, and three (15 per cent) received chemoradiotherapy. Three patients (15 per cent) were informed of the diagnosis but not treated for their condition.Conclusion:All of the 20 patients were still alive after a mean follow-up period of 50.8 months. Local treatment for mucosa-associated lymphoid tissue lymphoma of the head and neck should be the first choice in early-stage disease. However, prolonged follow up is important to determine these patients' long-term response to treatment.

Download Full-text

Robotic Transhiatal Esophagectomy in a Community Hospital: Evolution of Technique

The American Surgeon ◽

10.1177/000313481608200832 ◽

2016 ◽

Vol 82 (8) ◽

pp. 730-732

Author(s):

Vernon D. Horst ◽

Hetal D. Patel ◽

Stan C. Hewlett

Keyword(s):

Minimally Invasive ◽

Surgical Resection ◽

Early Stage ◽

Esophageal Resection ◽

Transhiatal Esophagectomy ◽

Robotic Technology ◽

Early Stage Disease ◽

Invasive Approach ◽

Stage Disease ◽

Perioperative Course

Esophageal cancer is an uncommon but highly lethal disease. Surgical resection is the gold standard of treatment for early-stage disease. Traditional surgical approach entailed significant convalescence, hospital stay, and morbidity and mortality. Transhiatal esophagectomy (THE) involves blind dissection of the esophagus with minimal mediastinal lymphadenectomy. Integration of robotic surgery is an alternate platform for minimally invasive approach while maintaining safety and following oncologic principles. We review our technique for minimally invasive THE using robotic technology, demonstrating the safety and efficacy of robotic technology surgery. We present a retrospective review of a single surgeon's data of patients treated with robotic-assisted THE, with a chart review to evaluate pathology, adequacy of surgical resection, nodal harvest, and perioperative course. Robotic THE (rTHE) shows promise as a valid option for esophageal resection, including premalignant and advanced stages of cancer. Adequate transhiatal mediastinal nodal resection can be performed with the robot.

Download Full-text